Upregulation of GRAIL is associated with remission of ulcerative colitis

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 295, Issue 1, 2008, Pages

  Egawa, Satoshi ^a   Iijima, Hideki ^a   Shinzaki, Shinichiro ^a   Nakajima, Sachiko ^a   Wang, Jun ^a   Kondo, Jumpei ^a   Ishii, Shuji ^a   Yoshio, Toshiyuki ^a   Irie, Takanobu ^a   Nishida, Tsutomu ^a   Kakiuchi, Yoshimi ^a   Yasumaru, Masakazu ^a   Yoshihara, Harumasa ^b   Kanto, Tatsuya ^a   Tsujii, Masahiko ^a   Tsuji, Shingo ^a   Hayashi, Norio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA ROSAI HOSPITAL   (Japan)

Author keywords

E3 ubiquitin ligase; Inflammatory bowel disease; T cell anergy; Tolerance

Indexed keywords

CBL PROTEIN; CORTICOSTEROID; IMMUNOMODULATING AGENT; MESALAZINE; MESSENGER RNA; PREDNISOLONE; PROTEIN GRAIL; PROTEIN ITCH; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; GRAIL PROTEIN; IONOMYCIN; IONOPHORE; ITCH PROTEIN, HUMAN; REPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTAPHERESIS; FEMALE; HUMAN; HUMAN CELL; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; ULCERATIVE COLITIS; UPREGULATION; WESTERN BLOTTING; ADOLESCENT; AGED; CELL CULTURE; DRUG EFFECT; GENETICS; LEUKAPHERESIS; METABOLISM; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; COLITIS, ULCERATIVE; FEMALE; HUMANS; IONOMYCIN; IONOPHORES; LEUKAPHERESIS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-CBL; REPRESSOR PROTEINS; RNA, MESSENGER; UBIQUITIN-PROTEIN LIGASES; UP-REGULATION;

EID: 51149086862     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.90242.2008     Document Type: Article

References (29)

1. Anandasabapathy N, Ford GS, Bloom D, Holness C, Paragas V, Seroogy C, Skrenta H, Hollenhorst M, Fathman CG, Soares L. GRAIL: an E3 ubiquitin ligase that inhibits cytokine gene transcription is expressed in anergic CD4+ T cells. Immunity 18: 535-547, 2003.
2. Andoh A, Tsujikawa T, Inatomi O, Deguchi Y, Sasaki M, Obata H, Mitsuyama K, Fujiyama Y. Leukocytapheresis therapy modulates circulating T cell subsets in patients with ulcerative colitis. Ther Apher Dial 9: 270-276, 2005.
3. Ayabe T, Ashida T, Kohgo Y. Centrifugal leukocyte apheresis for ulcerative colitis. Ther Apher 2: 125-128, 1998.
4. Blumberg RS, Saubermann LJ, Strober W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol 11: 648-656, 1999.
5. Boussiotis VA, Freeman GJ, Berezovskaya A, Barber DL, Nadler LM. Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1. Science 278: 124-128, 1997.
6. Duchmann R, May E, Heike M, Knolle P, Neurath M, Meyer zum Buschenfelde KH. T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans. Gut 44: 812-818, 1999.
7. Elson CO, Cong Y, McCracken VJ, Dimmitt RA, Lorenz RG, Weaver CT. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev 206: 260-276, 2005.
8. Faria AM, Weiner HL. Oral tolerance. Immunol Rev 206: 232-259, 2005.
9. Hustad CM, Perry WL, Siracusa LD, Rasberry C, Cobb L, Cattanach BM, Kovatch R, Copeland NG, Jenkins NA. Molecular genetic characterization of six recessive viable alleles of the mouse agouti locus. Genetics 140: 255-265, 1995.
10. Jenkins MK, Pardoll DM, Mizuguchi J, Chused TM, Schwartz RH. Molecular events in the induction of a nonresponsive state in interleukin 2-producing helper T-lymphocyte clones. Proc Natl Acad Sci USA 84: 5409-5413, 1987.
11. Knoflach P, Park BH, Cunningham R, Weiser MM, Albini B. Serum antibodies to cow's milk proteins in ulcerative colitis and Crohn's disease. Gastroenterology 92: 479-485, 1987.
12. Kostianovsky AM, Maier LM, Baecher-Allan C, Anderson AC, Anderson DE. Up-regulation of gene related to anergy in lymphocytes is associated with Notch-mediated human T cell suppression. J Immunol 178: 6158-6163, 2007.
13. Kraus TA, Toy L, Chan L, Childs J, Mayer L. Failure to induce oral tolerance to a soluble protein in patients with inflammatory bowel disease. Gastroenterology 126: 1771-1778, 2004.
14. Kruis W, Schreiber S, Theuer D, Brandes JW, Schutz E, Howaldt S, Krakamp B, Hamling J, Monnikes H, Koop I, Stolte M, Pallant D, Ewald U. Low dose balsalazide (1.5 g twice daily) and mesalazine (05 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (30 g twice daily) was superior in preventing relapses. Gut 49: 783-789, 2001.
15. Langdon WY, Hartley JW, Klinken SP, Ruscetti SK, Morse HC 3rd. v-cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas. Proc Natl Acad Sci USA 86: 1168-1172, 1989.
16. Macian F, Garcia-Cozar F, Im SH, Horton HF, Byrne MC, Rao A. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 109: 719-731, 2002.
17. MacKenzie DA, Schartner J, Lin J, Timmel A, Jennens-Clough M, Fathman CG, Seroogy CM. GRAIL is up-regulated in CD4+ CD25+ T regulatory cells and is sufficient for conversion of T cells to a regulatory phenotype. J Biol Chem 282: 9696-9702, 2007.
18. Maul J, Loddenkemper C, Mundt P, Berg E, Giese T, Stallmach A, Zeitz M, Duchmann R. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 128: 1868-1878, 2005.
19. Mueller DL. E3 ubiquitin ligases as T cell anergy factors. Nat Immun 5: 883-890, 2004.
20. Prioult G, Nagler-Anderson C. Mucosal immunity and allergic responses: lack of regulation and/or lack of microbial stimulation? Immunol Rev 206: 204-218, 2005.
21. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) vs. sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 298: 82-86, 1989.
22. Sartor RB. Induction of mucosal immune responses by bacteria and bacterial components. Curr Opin Gastroenterol 17: 555-561, 2001.
23. Schwartz RH. T cell anergy. Annu Rev Immunol 21: 305-334, 2003.
24. Seroogy CM, Soares L, Ranheim EA, Su L, Holness C, Bloom D, Fathman CG. The gene related to anergy in lymphocytes, an E3 ubiquitin ligase, is necessary for anergy induction in CD4 T cells. J Immunol 173: 79-85, 2004.
25. Sloan-Lancaster J, Evavold BD, Allen PM. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 363: 156-159, 1993.
26. Soares L, Seroogy C, Skrenta H, Anandasabapathy N, Lovelace P, Chung CD, Engleman E, Fathman CG. Two isoforms of otubain 1 regulate T cell anergy via GRAIL. Nat Immun 5: 45-54, 2004.
27. Takahashi I, Iijima H, Katashima R, Itakura M, Kiyono H. Clonal expansion of CD4+ TCRbetabeta+ T cells in TCR alpha-chain- deficient mice by gut-derived antigens. J Immunol 162: 1843-1850, 1999.
28. Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M, Shimizu J, Sakaguchi S. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 10: 1969-1980, 1998.
29. VanDemark AP, Hill CP. Structural basis of ubiquitylation. Curr Opin Struct Biol 12: 822-830, 2002.